Although surgical excision remains the preferred mode of treatment for BCC and SCC, intralesional IFN-α/β is a reasonable alternative to surgery for patients with poor hemostasis, those at high risk for poor wound healing, and those in whom surgery would be deforming or destroy function (e.g., cancers of the face and fingers). This evidence concerns the gene IFNA2 and cancer.